Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preserved vs Unpreserved Latanoprost Effect on Tear Film Thickness
NCT02585375Phase 4Unknown
- Sponsor
- Medical University of Vienna
- Start
- Sep 2015
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of latanoprost in Glaucoma and ocular hypertension (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Tear film thickness measured with high resolution optical coherence tomography (OCT) at 6 months. Status: unknown.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02585375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585375.